- Home
- CMMB vs RDHL Comparison
CMMB vs RDHL Comparison
Compare CMMB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | RDHL |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 5.4M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CMMB | RDHL |
|---|---|---|
| Price | $2.25 | $0.84 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 104.3K | ★ 145.8K |
| Earning Date | 05-21-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.71 |
| 52 Week High | $3.86 | $3.31 |
Technical Indicators
Market Signals| Indicator | CMMB | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 74.41 | 41.48 |
| Support Level | $1.48 | $0.76 |
| Resistance Level | $2.80 | $0.89 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 84.04 | 19.77 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.